甲状腺功能亢进症的孕前管理与后续妊娠中的甲状腺状态:一项基于人群的队列研究
该研究利用临床实践研究数据链数据库,纳入2000年1月至2017年12月15至45岁临床诊断甲状腺功能亢进症并随后妊娠的女性,比较不同孕前治疗策略对妊娠期甲状腺状态的影响。共纳入4712次妊娠,仅53.1%检测了促甲状腺激素,其中28.1%甲状腺状态不理想。孕前接受根治性治疗者较抗甲状腺药物起始妊娠者甲状腺状态不理想的比值比为4.72(95%CI 3.50-6.36)。
要点
- 妊娠期促甲状腺激素检测率仅53.1%,其中28.1%甲状腺状态不理想。
- 孕前根治性治疗者甲状腺状态不理想的OR为4.72(95%CI 3.50-6.36)。
- 2000至2017年孕前根治性治疗使用呈稳步下降。
核心结论
- 甲状腺功能亢进症女性妊娠期的管理不理想,尤其是孕前接受根治性治疗者,亟需改进。
- 需要更好的甲状腺监测和产前咨询以优化甲状腺状态、减少致畸药物暴露并最终降低不良妊娠结局风险。
研究设计与样本
- 利用临床实践研究数据链数据库的基于人群的队列研究,评估2000年1月至2017年12月所有15至45岁临床诊断甲状腺功能亢进症并随后妊娠的女性。
- 研究队列包含4712次妊娠。
- 根据孕前治疗比较妊娠期甲状腺状态:抗甲状腺药物使用至妊娠开始或之后、孕前根治性治疗(甲状腺切除术或放射性碘)、妊娠开始时无治疗。
主要发现
- 仅53.1%的妊娠检测了促甲状腺激素,其中28.1%显示甲状腺状态不理想(促甲状腺激素>4.0 mU/L或促甲状腺激素<0.1 mU/L且游离甲状腺素>参考范围)。
- 孕前接受根治性治疗的妊娠较抗甲状腺药物治疗期间起始妊娠者更可能出现甲状腺状态不理想(比值比4.72,95%CI 3.50-6.36)。
- 2000年至2017年观察到孕前根治性治疗使用稳步下降。
- 孕早期卡比马唑暴露的妊娠中32.6%转换为丙硫氧嘧啶,而丙硫氧嘧啶暴露的妊娠中6.0%转换为卡比马唑。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Optimal thyroid status in pregnancy is essential in reducing the risk of adverse outcomes. The management of hyperthyroidism in women of reproductive age poses unique challenges and it is unclear how preconception treatment strategies impact on thyroid status in subsequent pregnancy. OBJECTIVE: We aimed to determine trends in the management of hyperthyroidism before and during pregnancy and to assess the impact of different preconception treatment strategies on maternal thyroid status. METHODS: We utilized the Clinical Practice Research Datalink database to evaluate all females aged 15-45 years with a clinical diagnosis of hyperthyroidism and a subsequent pregnancy (January 2000 to December 2017). We compared thyroid status in pregnancy according to preconception treatment, namely, (1) antithyroid drugs up to or beyond pregnancy onset, (2) definitive treatment with thyroidectomy or radioiodine before pregnancy, and (3) no treatment at pregnancy onset. RESULTS: Our study cohort comprised 4712 pregnancies. Thyrotropin (TSH) was measured in only 53.1% of pregnancies, of which 28.1% showed suboptimal thyroid status (TSH >4.0 mU/L or TSH <0.1 mU/L plus FT4 >reference range). Pregnancies with prior definitive treatment were more likely to have suboptimal thyroid status compared with pregnancies starting during antithyroid drug treatment (odds ratio 4.72, 95% CI 3.50-6.36). A steady decline in the use of definitive treatment before pregnancy was observed from 2000 to 2017. One-third (32.6%) of first trimester carbimazole-exposed pregnancies were switched to propylthiouracil while 6.0% of propylthiouracil-exposed pregnancies switched to carbimazole. CONCLUSION: The management of women with hyperthyroidism who become pregnant is suboptimal, particularly in those with preconception definitive treatment, and needs urgent improvement. Better thyroid monitoring and prenatal counseling are needed to optimize thyroid status, reduce teratogenic drug exposure, and ultimately reduce the risk of adverse pregnancy outcomes.
引用
- Minassian C, Allen LA, Okosieme O, et al. Preconception Management of Hyperthyroidism and Thyroid Status in Subsequent Pregnancy: A Population-Based Cohort Study. J Clin Endocrinol Metab. 2023. PMID: 37200150. doi:10.1210/clinem/dgad276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。